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ABSTRACT 
Chronic kidney disease (CKD) is common and presents an increasing burden to patients and health 
services. However, the optimal model of care for patients with CKD is unclear.  We systematically 
reviewed the clinical effectiveness of different models of care for the management of CKD. A 
comprehensive search of eight databases was undertaken for articles published from 1992 to 2016. 
We included randomised controlled trials which assessed any model of care in the management of 
adults with pre-dialysis CKD, reporting renal, cardiovascular, mortality and other outcomes. Data 
extraction and quality assessment was carried out independently by two authors.  Results were 
summarized narratively. Nine articles (seven studies) were included.  Four models of care were 
identified: nurse-led, multidisciplinary specialist team, pharmacist-led and self-management.  Nurse 
and pharmacist-led care reported improved rates of prescribing of drugs relevant to CKD.  
Heterogeneity was high between studies and all studies were at high risk of bias. Nurse-led care and 
multidisciplinary specialist care were associated with small improvements in blood pressure control.  
Evidence of long term improvements in renal, cardiovascular or mortality endpoints was limited by 
short follow up. We found little published evidence about the effectiveness of different models of 
care to guide best practice for service design, although there was some evidence that models of care 
where health professionals deliver care according to a structured protocol or guideline may improve 
adherence to treatment targets.  
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INTRODUCTION 
Chronic kidney disease (CKD) is common with an estimated global prevalence of 11-13%.1  CKD 
prevalence is rising, driven by an ageing population and the increasing prevalence of obesity, 
diabetes and hypertension.2  As a result, CKD presents an increasing burden to health services 3.  
Most patients with mild to moderate CKD are asymptomatic, but have a higher risk of cardiovascular 
disease and are at risk of developing anemia, metabolic bone disease or progressing to end-stage 
renal disease (ESRD) requiring renal replacement therapy (RRT).4, 5  Interventions recommended to 
reduce the risk of these endpoints include lifestyle modification, anti-hypertensive medication 
(specifically inhibitors of the renin-angiotensin-aldosterone system), lipid modification, and 
achieving glycemic control in patients with diabetes mellitus.5    
 
Patients with mild to moderate CKD are usually managed within primary care and referred to 
specialist care as the condition progresses.6  However, efforts to increase the awareness of CKD have 
led to the identification of large numbers of patients with mild to moderate CKD, creating challenges 
in the design and delivery of health services.5  How health services should be organized to support 
patients with CKD most effectively, is unclear.5, 7    
 
The existing literature on interventions to improve outcomes in CKD is of predominantly individual 
interventions, eg psychological support, pharmacist medication review, anti-hypertensive 
medication.8-10  In clinical practice, many individual interventions are used together for an 
individual patient. This multidimensional approach, grouping packages of interventions 
forms a ‘model of care’. Understanding the optimal model of care for CKD patients is important 
and would allow the design of health services to maximize health and well-being whilst making best 
use of limited resources.11   In this systematic review, we assessed the relative effectiveness of 
different models of care for the management of CKD for a range of outcomes.  
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METHODS 
Data sources and searches 
Cochrane methodology was followed, with the exception that only one reviewer screened titles of 
publications identified from searches. Electronic searches were performed to identify articles 
published between 1992 and October 2014, and updated through to June 2016.  A search strategy 
was developed for MEDLINE, and adapted for seven other databases (File S1), which was 
constructed to be highly sensitive to take account of the lack of consistent terminology to identify 
models of care studies. The reference list of included articles and any systematic reviews identified 
from the searches were also checked.  All citations were downloaded to Refworks Reference 
Management Software (Version 2.0).  Titles were screened by one author (LR, RN, EG or CB). 
Abstracts and full text were screened independently by two authors (LR, RN, EG, CB, AM or PS). Any 
disagreements were resolved by discussion and consensus. 
 
Study selection 
Studies were included which compared any two multidimensional models of care in adults with pre-
dialysis CKD and reported any of a defined list of outcomes.  We included randomized controlled 
trials (RCTs), published in English from 1992 onwards (10 years prior to the KDIGO CKD guidelines).6  
We excluded observational studies in order to limit the potential for bias. For this review, a model of 
care must have been capable of delivering more than one type of intervention targeted at more than 
one aspect of disease management.   
 
Data extraction and quality assessment 
Standardized data extraction forms were developed.  Data extraction was carried out independently 
by two authors and any disagreements were resolved through discussion and consensus.  Data 
collected included setting, population details, quality assessment items, details of the intervention, 
model of care and comparison management details, and outcomes of interest.  Quality assessment 
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was carried out using the Cochrane Collaboration’s ‘Risk of Bias’ tool, without modification.12  This 
uses pre-specified grading criteria to categorize the degree of risk as either low, unclear or high for 
multiple domains.  The highest degree of risk for any of these domains is then used to determine the 
overall risk of bias.  Risk of bias was assessed independently by two reviewers and any differences 
were resolved by consensus.   
 
Outcomes 
Outcomes of interest included clinical endpoints (progression of CKD, progression to ESRD without 
RRT, initiation of RRT, cardiovascular endpoints, mortality), management of risk factors (blood 
pressure, weight, anaemia, bone disease), prescribing of relevant medications, patient education, 
quality of life, health service satisfaction, health service use and health service costs.   
 
Data synthesis and analysis 
Study results were tabulated and reported qualitatively. Due to high levels of heterogeneity we were 
unable to perform a meta-analysis.   
 
RESULTS 
The searches identified 8672 citations (Figure 1).  After removal of duplicates, title screening and 
abstract screening, 58 articles remained.   Following full text review, 9 articles (7 studies) were 
deemed to meet the eligibility criteria and were included. Two trials were conducted in the 
Netherlands, two in the USA, one in Canada, one in China, and one in Taiwan. The characteristics of 
the included studies are shown in Table S2.  
 
Description of studies and interventions 
Studies were categorized according to the model of care assessed (Table 1).  Three examined nurse-
led care,13-17 two examined multi-disciplinary specialist care,18, 19 one examined pharmacist care20 
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and one examined a form of patient self-management care termed ‘self-management support.21  
Studies ranged in size from 54 to 2199 participants. In the studies examining nurse-led care and 
multi-disciplinary specialist care, the intervention was compared against ‘usual care’ for the 
respective setting.  However, in the studies examining pharmacist care and self-management 
support, these interventions were delivered in addition to usual care.  The follow-up period for most 
studies was typically less than two years, with the exception of the MASTERPLAN study13-15 
examining nurse-led care, which had a mean follow-up of 5.7 years and Harris et al.19 examining 
multi-disciplinary specialist care which had a five year follow-up period.  A common feature to all of 
the models of care described in the studies was an increased emphasis on treatment that adhered to 
a standardized protocol or guideline.   
 
Nurse-led care 
In the MASTERPLAN study,13-15 the intervention group received care delivered by specialist nurses 
working in secondary care under the supervision of nephrologists whilst the control group received 
nephrologist care.  In Scherpbier de Haan et al.,16 the intervention group received care delivered by 
nurse practitioners in a primary care setting under the supervision of General Practitioners (GPs) 
whilst the control group received usual care from GPs with the assistance of nurse practitioners.  In 
Barrett et al.,17 the intervention group received care led by nurses in primary care who could request 
assistance of GPs or nephrologists, as required, whilst the control group received usual care led by 
GPs. 
 
Multidisciplinary specialist care 
In Chan et al.,18 the intervention group received structured multidisciplinary care from a 
diabetologist, endocrine trainees, diabetic nurses and a dietician in a secondary care setting whilst 
the control group received usual care as led by a diabetologist or general physician.  In Harris et al.,19 
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the intervention group received structured multidisciplinary care from a nephrologist, renal nurse, 
dietician and social worker in a secondary care setting whilst those in the control group received 
usual care from GPs with other health professional input if requested. 
   
Pharmacist care 
In Cooney et al.,20 the intervention group received pharmacy care input prior to previously arranged 
GP appointments whilst the control group received usual GP care only.   
 
Self-management 
In Chen et al.,21 the intervention group participated in an intensive multidisciplinary programme to 
support self-management alongside usual nephrologist care whilst the control group received usual 
nephrologist care only.   
 
Risk of bias 
Using the Cochrane assessment of bias tool, all included studies were classified as having high risk of 
bias, primarily because participants and personnel were not blinded in any of the studies although 
this would have been difficult due to the type of intervention being assessed (Table S3).  When 
blinding was removed as a key domain, five out of seven studies remained at high risk of bias with 
the other two at unclear risk of bias.  In three studies the randomization process was not described 
clearly.  Sealed envelopes were used to conceal allocation status in one study18 and in the remaining 
studies allocation concealment was either not described or not performed.  Blinding of outcome 
assessment was clearly described in only three studies.  Outcome reporting was incomplete in three 
studies.  In two of these studies the reasons for losses to follow-up were not clear19, 21 and in the 
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third the authors reported higher rates of use of drugs blocking the renin-angiotensin-aldosterone 
system but do not report the data to support this.16  The potential for selective reporting was 
present or unclear in six studies as the original study protocol was unavailable (86%).  Other sources 
of bias identified included the potential for recruitment bias in one study,17 lack of assessment to 
protocol adherence,17 and anomalies in the way patient flow was described.21   
 
Outcomes 
Renal  
All seven studies reported renal outcomes (Table 2).  Of the three studies investigating nurse-led 
care, one reported a small statistically significant reduction in mean rate of decline in eGFR in the 
intervention group (1.26 vs 1.71 ml/min/1.73m2/year, p=0.01, mean follow-up 5.7 years).13-15  
However, in the same study there was no statistically significant difference in the number of 
reported ESRD events or the number of patients with greater than 50% rise in serum creatinine.   
The remaining two studies found no effect of nurse-led care on renal outcomes.16, 17  Two studies 
investigated multidisciplinary specialist care and found no effect on renal outcomes.18, 19  One study 
investigating pharmacist care found no effect on renal outcomes.20  One small study investigating 
self-management support found that the absolute eGFR was higher in the intervention group after 
one year (29.1 vs 15.7 ml/min/1.73m2, p=0.04) and that the number of patients with a greater than 
50% decline in eGFR was lower (1 vs 9, p<0.05).  However, there was a non-significant difference in 
mean eGFR at baseline and there was no difference in the number of patients who progressed to 
requiring RRT.21   
 
Cardiovascular 
Two studies reported cardiovascular outcomes.  The MASTERPLAN study13-15 which investigated 
nurse led care found no significant difference between groups for the composite cardiovascular (HR 
0.90, 95% CI 0.58-1.39) or composite ischaemic heart disease endpoint (HR 1.15, 95% CI 0.71-1.86).  
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Chan et al.18 which investigated multidisciplinary specialist care found no significant difference 
between groups for their composite cardiovascular endpoint.   
 
Mortality 
Five studies reported mortality rates (Table 3).  None found any significant difference in mortality 
between intervention and comparator models of care.   
 
Blood Pressure 
Five studies reported blood pressure outcomes (Table S4).  Three of these studies investigated 
nurse-led care.  One found a statistically significant reduction in final mean systolic (134 vs 
136mmHg) and diastolic (77 vs 79mmHg) blood pressure in the intervention group.13-15  One found a 
statistically significant increase in the number of patients with systolic blood pressure <130mmHg 
(44.4% vs 21.6%) and diastolic blood pressure <80mmHg (71.1% vs 50.0%) at one year.16  However, 
the third found no significant improvement in blood pressure control.17  One study investigated 
multi-disciplinary specialist care and found a statistically significant increase in the proportion of 
patients achieving a blood pressure <130/80mmHg (49% vs 27%).18  One study investigated 
pharmacist care and found no significant difference in blood pressure outcomes.20    
 
Prescribing 
Six studies reported drug prescribing rates (Table S5).  Three investigated nurse-led care and all 
demonstrated statistically significant increases in the prescribing of relevant drugs.  These included 
ACE inhibitors,13-16 lipid-modifying agents,13-17 Aspirin,13-15 Vitamin D,13-16 and iron supplements.17  
There was no significant difference in the rate of prescribing for phosphate binders.13-15 Two studies 
investigated multidisciplinary specialist care.  One demonstrated no significant difference in rates of 
prescribing.19  The other demonstrated a significantly higher rate of prescribing for ACE inhibitors 
although this was also present at baseline.18  One study investigated pharmacist care and 
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demonstrated a significantly higher rate of prescribing for Vitamin D and bicarbonate at the end of 
the study but this was not demonstrated for phosphate binders or ACE inhibitors.20   
 
Body Mass Index and weight 
Three studies reported body mass index (BMI) or weight (Table S6).  None demonstrated any 
significant improvement in weight or BMI.   
 
Health service use and costs 
Three studies reported on health service use (Table S6).  One study investigating nurse-led care 
found that whilst the mean number of total visits (including nurse visits) per year was higher in the 
intervention group (7.0 vs 4.7, p<0.001), the mean number of physician visits per year was lower (2.8 
vs 3.7, p<0.001). Although the study was not designed to include a cost-benefit analysis, a crude 
estimate of costs and savings is reported as a supplement.13-15 One study investigating 
multidisciplinary specialist care found that the mean total number of outpatient clinic visits at 3-5 
years was higher in the intervention group (26.0 vs 18.0, p<0.001) but demonstrated no difference in 
the number of hospitalizations or emergency department visits. The annual direct costs of the 
intervention were reported as $484 per intervention patient.19  One small study investigating self-
management support found the total number of hospitalizations at 12 months was significantly 
lower in the intervention group (5 vs 12, p<0.05).21   
 
Patient education 
One study investigating self-management support found a statistically significant increase in patient 
education status using a standardized CKD knowledge score in the intervention group at one year 
(10.13 vs 5.51, p<0.01).21   
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Quality of Life 
One study investigating pharmacist care found no significant difference between intervention and 
comparator model of care with regards to quality of life outcomes.20   
 
Patient satisfaction 
Two studies reported satisfaction on with care, but only in the intervention group. Both reported 
high satisfaction with care received.17, 20 
 
DISCUSSION 
To our knowledge, this is the first systematic review of RCTs of the effectiveness of different models 
of care for CKD against a range of outcomes.  The seven studies included in this review evaluated 
four different categories of models of care.  Those examining nurse-led care and multi-disciplinary 
specialist care compared these models of care against usual care, whereas in those examining 
pharmacist-care and self-management support, the interventions were delivered in addition to usual 
care.  
 
Although the majority of studies did not find a significant effect on outcomes, there was some 
evidence of improved short term clinical outcomes (e.g. blood pressure) and care utilization 
outcomes (e.g. prescribing).  This was particularly true where models of care were protocol-driven 
through nurse and pharmacist led approaches. There was little evidence that these improvements 
translated into improvements in the rates of key clinical outcomes, including renal, cardiovascular or 
mortality endpoints.  However, these were not reported in all studies with only two studies 
reporting cardiovascular outcomes and five reporting mortality.  Furthermore, only two studies 
followed patients for more than two years and had statistical power calculations performed to 
ensure they were of sufficient size to detect a difference.   
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With regards to non-clinical outcomes, there was some evidence that nurse-led care led to a 
reduced number of physician visits, although this was necessarily associated with an increased 
number of nurse visits.  The only study to investigate the addition of self-management support to 
usual care found a clinically and statistically significant reduction in the rate of hospital admissions in 
the intervention group.  However, as this was a small study, the results should be treated with 
caution until replicated in a larger population.   
 
Although there was significant heterogeneity between studies, there were common elements 
between studies and between different categories of model of care.  In the majority of studies there 
was an increased use of either nursing or allied health professionals to deliver care.  In addition, in 
the majority of studies, health professionals used a structured protocol or guideline focused on 
specific treatment targets to help them deliver care.  This may explain why improvements in some 
outcomes were noted across different categories of models of care. There may also be variation with 
regard to country, setting, clinical practice, resources and practitioners’ roles, eg qualified to 
prescribe or otherwise.  
 
Other reviews of CKD models of care have included observational studies alongside RCTs.  One 
review investigated multidisciplinary care in the management of CKD and found some evidence of 
improved renal and metabolic outcomes.22  However, this systematic review included four studies, 
two of which were observational, and the majority of the positive findings were derived from the 
non-randomized observational studies.  Of the two RCTs within this review, one was included within 
our review19 and the other was excluded as it did not meet our definition of a multidimensional 
model of care.23  Another review investigated pharmacist interventions in the management of CKD.24  
Most of the studies included were observational but it found some evidence that pharmacist 
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interventions led to improved prescribing and metabolic outcomes.  None of these studies met the 
inclusion criteria for our review.   
 
Our study has many strengths.  With the exception of the initial title-screening, all parts of the 
selection process, quality assessment and data extraction were performed independently by two 
reviewers to limit the potential for bias.  Eight databases were searched using a highly sensitive 
search strategy to take account of the lack of consistent terminology to identify models of care 
studies.  The search was restricted to RCTs to limit the potential for bias.25  However, there are study 
limitations.  Although the search strategy was chosen to maximize sensitivity there may be relevant 
published studies not identified by our searches.  Unpublished studies were not included, which may 
leave the review at risk of reporting bias.   In addition, restricting the review to only include RCTs 
meant that any good quality observational studies were not included.  The RCTs identified, however, 
were all classified as having a high risk of bias. 
 
Despite the increasing recognition of the importance of identifying effective models of care for 
patients with long-term conditions such as CKD, there was little published evidence to guide best 
practice for service design.26  This review identified only seven studies assessing four different 
multidimensional models of care between them.  One potential reason may be perceived difficulty in 
designing studies to assess complex interventions. However, there are solutions including use of 
cluster RCTs and stepped wedge designs.25  When a model of care is identified as improving 
outcomes, it is important to carefully define the intervention and identify which elements of care are 
responsible as this allows designers to improve services with minimal change. Models of care should 
be evaluated as complex interventions including the emerging approaches to shared care.25   
 
In conclusion despite the growing burden from CKD, there was little published evidence about the 
effectiveness of different models of care to guide best practice for service design. There was limited 
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evidence, from studies classified as having a high risk of bias, that models of care where nurses or 
allied health professionals deliver care according to a structured protocol or guidelines may improve 
adherence to treatment targets; and also that self-management may reduce hospitalizations. In 
order to drive future policy recommendations, a multi-centre RCT of a highly protocolized model of 
care vs usual care that randomized on centre (considering a step-wedge methodology if necessary), 
with long follow-up of at least five years to allow assessment of hard outcomes such as mortality, 
readmission and health service use in addition to short term process related outcomes such as BP, 
and of sufficient size is required. To aid intervention design for future RCTs, a review of 
observational studies is recommended. 
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SUPPORTING INFORMATION 
 
File S1: Search strategy 
Table S2: Characteristics of includes studies 
Table S3: Risk of bias in included studies 
Table S4: Blood pressure outcomes 
Table S5: Prescribing outcomes 
Table S6: Other outcomes 
 
 
 
  
19 
 
FIGURE LEGEND 
Figure 1.  Flow diagram of search and study selection process 
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Table 1. Description and components of models of care 
 
GP, general practitioner; CKD, chronic kidney disease 
✓ included, ✕ not included 
† Intervention provided in addition to usual care (equivalent to the comparator group) 
  
Study
Number of 
participants
Follow-up 
(years)
Intervention 
Model of Care
Frequency 
of contact
Team Members 
(intervention)
Use of 
protocol
Patient 
Education
Lifestyle 
advice
Prescribing
Psychosocial 
support
Comparator 
Model of Care
Details of 
Comparator 
Model of Care
Peeters, Van 
Zuilen et al
Masterplan Study
788 5.7 (mean) Nurse-led care 3 monthly Nurses, Nephrologist
✓ ✓ ✓ ✓ ✕
Nephrologist-led 
care
Not stated
Scherpbier de 
Haan et al
164 1 (limited) Nurse-led care 3 monthly Nurse, Nephrologist, 
General practitioner
✓ ✕ ✓ ✓ ✕
GP-led care Not stated
Barrett et al 474 2.0 (median) Nurse-led care 4 monthly Nurse, Nephrologist, 
GP
✓ ✕ ✓ ✓ ✕
GP-led care Not stated
Chan et al 205 2 Multi-disciplinary 
specialist care
3 monthly Diabetologist, Diabetic 
nurse and dietician. 
✓ ✕ ✓ ✓ ✕
Physician-led care Not stated
Harris et al 437 5 Multi-disciplinary 
specialist care
3-6 monthly Nephrologist, Renal 
nurse, Dietician, Social 
worker
✓ ✕ ✕ ✓ ✕
GP-led care Not stated
Cooney et al 2199 1 (limited) Pharmacist care† Prior to GP 
review
Pharmacist, GP
✓ ✓ ✓ ✓ ✕
GP-led care Not stated
Chen et al 54 1 (limited) Self-management 
support†
Weekly Nephrologist, 
Dietician, Peers, CKD 
nurse specialist
✓ ✓ ✓ ✕ ✓
Nephrologist-led 
care
Not stated
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Table 2. Renal outcomes 
Study Study Category Outcomes Reported Intervention Control Significance 
Peeters, Van Zuilen 
(2011, 2012, 2014) 
Nurse-led care Mean Rate of eGFR decline(ml/min/1.73m2/year) 
(mean, Standard Deviation) 
1.26 (0.12) 1.71 (0.12) HR 0.45 (95%CI 0.12-
0.78), p=0.01 
  
Renal replacement therapy events (n) 77 89 HR 0.75 (95%CI 0.51-
1.08), p=0.12 
  
≥50% rise in serum creatinine at end of study (n) 130 153 HR 0.81 (95% CI 0.64-
1.03), p=0.09 
Scherpbier de Haan 
(2013) 
Nurse-led care eGFR (ml/min/1.73m2) at 1 year (mean, Standard 
Deviation) 
48.6 (8.7) 49.4 (8.0) p=0.83 
Barrett (2011) Nurse-led care Decline in eGFR >4ml/min/1.73m2 after 20 months (%) 17.0 13.9 p=0.43 
Chan (2009) Multidisciplinary 
specialist care 
ESRD (Creatinine >500μmol/L) at follow-up (%) 
Renal replacement therapy events (%) 
11.0 
6.6 
14.6 
8.3 
p=0.14 
p=0.28 
Harris (1998) Multidisciplinary 
specialist care 
CrCl (ml/min) at follow-up (mean, Standard Deviation) 30 (16) 34 (24) p=0.10 
Cooney (2015) Pharmacist-led care ESRD at 1 year (number, %) 26 (2.4) 20 (1.8) p=0.28 
Chen (2011) Self-management 
support 
eGFR  (ml/min/1.73m2) at baseline (mean, Standard 
Deviation) 
27.1 (14.8) 23.6 (13.1) p=0.36 
  
eGFR  (ml/min/1.73m2)at 1 year (mean, Standard 
Deviation) 
29.1 (20.6) 15.7 (10.7) p=0.04 
  
Renal replacement therapy events (number, %) 4 (14.5) 5 (18.5) p>0.05 
    Greater than 50% decline in eGFR from baseline 
(number, %) 
1 (3.7) 9 (33.3) p<0.05 
eGFR, estimated Glomerular Filtration Rate; CrCl, creatinine clearance; ESRD, end stage renal disease; HR, hazard ratio; CI, confidence interval 
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Table 3. Mortality 
Study Study Category Outcomes Reported Intervention Control Intervention 
Minus Control (%) 
Significance 
Peeters, 
Van Zuilen 
(2011, 
2012, 2014) 
Nurse-led care Deaths after mean 
follow-up 5.7 years (n, %) 
68/395 
(17.2) 
74/393 
(18.8) 
-1.6 HR 0.85 (95% 
CI 0.62-1.18), 
p=0.34 
Harris 
(1998) 
Multidisciplinary 
specialist care 
Deaths after 3-5 years (n, 
%) 
59/206 
(28.6) 
77/231 
(33.3) 
-4.7 p=0.29 
Chan (2009) Multidisciplinary 
specialist care 
Deaths after 2 years (n, 
%) 
8/104 (7.6) 11/101 
(10.9) 
-8.8 Not significant 
Chen (2011) Self-management 
support 
Deaths at 1 year (n, %) 0/ 27 (0) 1/27 (3.7) -3.7 Not reported 
Cooney 
(2015) 
Pharmacist-led 
care 
Deaths at 1 year (n, %) 50/1070 
(4.7) 
74/1129 
(6.6) 
-1.9 p=0.06 
n, number; HR, hazard ratio; CI, confidence interval 
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File S1. Search strategy 
 
Databases searched 
 
MEDLINE, EMBASE, Health Management and Information Consortium, Central Nursing and Allied 
Health Literature, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic 
Reviews, Database of Abstracts of Reviews of Effects and the Health Technology Assessment. 
 
MEDLINE search terms 
 
1 Renal Insufficiency, Chronic/di, dh, dt, ec, mo, nu, pc, rh, su, th [Diagnosis, Diet Therapy, Drug 
Therapy, Economics, Mortality, Nursing, Prevention & Control, Rehabilitation, Surgery, Therapy] 
2 exp Diabetic Nephropathies/di, dh, dt, ec, mo, nu, pc, rh, su, th [Diagnosis, Diet Therapy, Drug 
Therapy, Economics, Mortality, Nursing, Prevention & Control, Rehabilitation, Surgery, Therapy] 
3 exp Uremia/di, dh, dt, mo, nu, pc, rh, su, th [Diagnosis, Diet Therapy, Drug Therapy, Mortality, 
Nursing, Prevention & Control, Rehabilitation, Surgery, Therapy] 
4 (CKD or CKF or CRD).tw. 
5 chronic kidney disease.tw. 
6 chronic renal insufficiency.tw. 
7 diabetic kidney disease.tw. 
8 diabetic nephropath$.tw. 
9 diabetic kidney failure.tw. 
10 pre-dialysis.tw. 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 models, nursing/ 
13 models, organizational/ 
14 exp Patient Care/ae, ec, is, mt, mo, st, sn, ut [Adverse Effects, Economics, Instrumentation, 
Methods, Mortality, Standards, Statistics & Numerical Data, Utilization] 
15 exp Patient Care Management/ec, mt, og, st, sn, td, ut [Economics, Methods, Organization & 
Administration, Standards, Statistics & Numerical Data, Trends, Utilization] 
16 "referral and consultation"/ or gatekeeping/ or remote consultation/ or secondary care/ or 
tertiary healthcare/ 
17 Patient Education as Topic/ec, ed, ma, mt, og, st, sn, td, ut [Economics, Education, Manpower, 
Methods, Organization & Administration, Standards, Statistics & Numerical Data, Trends, 
Utilization] 
18 Nurse Clinicians/og [Organization & Administration] 
19 preventive health services/ or diagnostic services/ or "early intervention (education)"/ or early 
medical intervention/ or health education/ 
20 model? of care.tw. 
21 care system.tw. 
22 care program$.tw. 
23 care pathway.tw. 
24 nursing model.tw. 
25 organi?ational model.tw. 
26 (nephrol$ adj4 refer).tw. 
27 (patient adj4 refer).tw. 
28 preventive health services.tw. 
29 (multidisciplinary adj3 care).tw. 
30 (interdisciplinary adj3 care).tw. 
31 low clearance clinic.tw. 
32 shared care.tw. 
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33 clinical pathway.tw. 
34 renal service.tw. 
35 nephrol$ service.tw. 
36 integrated care.tw. 
37 (nurse-led adj3 care).tw. 
38 (nurse-based adj3 care).tw. 
39 (nurse-led adj3 clinic).tw. 
40 (nurse-led adj3 program$).tw. 
41 (nurse-coordinated adj3 care).tw. 
42 (nurse-coordinated adj3 clinic).tw. 
43 patient led.tw. 
44 self-led.tw. 
45 nephrol$ care.tw. 
46 ((patient or people) adj3 education program$).tw. 
47 nurse clinicians.tw. 
48 self management.tw. 
49 case manag$.tw. 
50 disease management program$.tw. 
51 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 
or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 or 47 or 48 or 49 or 50 
52 11 and 51 
53 animals/ 
54 52 not 53 
55 limit 54 to (english language and yr="1992 -Current") 
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Table S2. Characteristics of included studies 
 
CKD, chronic kidney disease; CrCl, creatinine clearance ml/min; eGFR, estimated glomerular filtration rate MDRD formula, ml/min/1.73m2; BP, blood 
pressure; BMI, body mass index; GP, general practitioner 
a in addition to usual care (equivalent to the comparator group)  
Study ID Population Setting Intervention Comparator Outcomes Measured Length of Study (years)
Peeters, Van Zuilen 
et al  (12,14)
Masterplan Study
Netherlands
Age >18 years, CKD 
(CrCl 20-70)
Secondary care Nurse-led care Nephrologist-led 
care
Renal, Death, Cardiovascular, 
BP, BMI, Prescribing, Health 
service use
5.7 (mean follow-up)
Scherpbier de Haan 
et al (15)
Netherlands
Age >18 years, CKD 
(eGFR <60)
Primary and 
secondary care
Nurse-led care GP-led care Renal, Death, BP, BMI, 
Prescribing, Quality of Life
1
Barrett et al (16)
Canada
Age 40-75 years, CKD 
(eGFR 25-60)
Primary care Nurse-led care GP-led care Renal, BP, Prescribing 2.0 (median follow-up)
Chan et al (17)
China
Age 35-75 years, 
Type 2 Diabetes, CKD 
(serum creatinine 
150-350μmol/L)
Secondary care Multi-disciplinary 
specialist care
Physician-led 
care
Renal, Death, Cardiovascular, 
BP, Prescribing
2
Harris et al (18)
USA
CKD (CrCl <50) Secondary care Multi-disciplinary 
specialist care
GP-led care Renal, Death, Prescribing, BMI, 
Health service use
5
Cooney et al (19)
USA
Age 18-85 years, CKD 
(eGFR< 45)
Primary care Pharmacist carea GP-led care Renal, Death, BP, Prescribing
Quality of life, PTH 
measurements
1
Chen et al (20)
Taiwan
Age 18-80 years, CKD 
(eGFR 30-60)
Secondary care Self-
management 
supporta
Nephrologist-led 
care
Renal, Death, Health service 
use, Patient education
1
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Table S3. Risk of bias in included studies 
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Peeters, Van 
Zuilen et al
Nurse-led care
+ ? - + + ? + -
Scherpbier de 
Haan et al
Nurse-led care
? - - ? - - + -
Barrett et al Nurse-led care
? ? - - + ? - -
Chan et al Multidisciplinary 
specialist care + + - - + + - -
Harris et al Multidisciplinary 
specialist care ? ? - ? - ? + - + Low Risk
Cooney et al Pharmacist care
+ ? - + + ? + - ? Unclear Risk
Chen et al Self-
management 
support
+ ? - + - ? - - - High Risk
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Table S4. Blood pressure outcomes 
 
CI, confidence interval; SD, standard deviation 
  
Study Study Category Outcomes Reported Intervention Control Significance
Peeters, Van Zuilen 
(2011,2012,2014)
Nurse-led care Final systolic blood Pressure (mmHg )(mean, 95%CI) 134 (132-135) 136 (135-138) p=0.03
Final diastolic blood Pressure (mmHg)(mean, 95%CI) 77 (77-78) 79 (78-80) p=0.01
Scherpbier de 
Haan (2013)
Nurse-led care Change in systolic blood pressure at 1 year (mmHg) (mean, 95% CI) -8.1 (-11.3, -4.8) 0.2 (-3.6-3.8) Not reported
Patients with systolic blood pressure <130mmHg at 1 year (n, %) 40 (44.4) 16 (21.6) p=0.003
Change in diastolic blood pressure at 1 year (mmHg) (mean, 95% CI) -1.1 (-3.2, 1.0) 0.5 (-1.8, 2.9) Not reported
Patients with diastolic blood pressure <80mmHg (n, %) 64 (71.1) 37(50) p=0.007
Barrett (2011) Nurse-led care Patients with blood pressure <130/80mmHg (2 years) (%) 63 47 p=0.76
Chan (2009) Multidisciplinary 
specialist care
Last available systolic blood pressure (mmHg) (mean, SD) 135 (25) 137 (21) p=0.15
Last available diastolic blood pressure (mmHg) (mean, SD) 68 (12) 71 (12) p=0.02
Patients with blood pressure <130/80 mmHg (%) 49 27 p<0.01
Cooney (2015) Pharmacist-led 
care
Final systolic blood pressure in patients with baseline blood 
pressure >130/80 (mmHg) (mean, SD)
135.1 (17.4) 134.4 (17.6) p=0.57
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Table S5. Prescribing outcomes 
 
ACE, angiotensin converting enzyme; LDL, low density lipoprotein 
  
Study Study Category Outcomes Reported Intervention Comparator Significance
Peeters, Van Zuilen 
(2011, 2012, 2014)
Nurse-led care Use of ACE inhibitors at end of follow-up (%) 90.0 83.0 p<0.001
Use of Statin at end of follow-up (%) 84.0 75.0 p<0.001
Use of Aspirin at end of follow-up(%) 69.0 49.0 p<0.001
Use of Vitamin D at end of follow-up(%) 47.0 37.0 p=0.002
Use of Phosphate binder at end of follow-up(%) 15.0 18.0 p=0.14
Scherpbier de Haan 
(2013)
Nurse-led care Use of lipid-modifying agent (%) (1 year) 73 59 p=0.004
Use of Vitamin D (%)(1 year) 16 1 p=0.002
Use of ACE inhibitor or ARB (%) (1 year) 81 73 p=0.01
Barrett (2011) Nurse-led care Use of statin in patients with LDL >2.5mmol/L (%) (2 years) 84 51 p=0.0003
Use of iron supplement in patients with iron saturation <0.2 (%) 
(1 year)
35 14 p=0.005
Chan (2009) Multidisciplinary 
specialist care
Use of ACE inhibitors or ARB (%) (2 years) 69 49 p<0.01
Harris (1998) Multidisciplinary 
specialist care
Use of ACE inhibitors at 3-5 years (%) 36 33 p=0.40
Cooney (2015) Pharmacist led care Use of ACE inhibitor or ARB at end of study (%) 64.2 61.7 p=0.41
Use of Phosphate binder at end of study (%) 22.4 23.5 p=0.87
Use of Vitamin D at end of study (%) 61.9 52.4 p=0.004
Use of Bicarbonate at end of study (%) 24.0 13.0 p=0.03
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Table S6. Other outcomes 
 
BMI, body mass index; SD, standard deviation; CI, confidence interval 
 
 
Study Study Category Outcomes Reported Intervention Control Satistical 
Significance
Weight and BMI
Peeters, Van Zuilen 
(2011, 2012, 2014)
Nurse-led care BMI at end of study (kg/m2) (mean, 95%CI) 27.0 (26.6, 27.5) 27.1 (26.6, 27.6) p=0.83
Scherpbier de 
Haan (2013)
Nurse-led care BMI at 1 year (kg/m2) (mean, SD) 28.9 (4.7) 28.4 (4.6) p=0.68
Harris (1998) Multidisciplinary 
specialist care
Weight at 3-5 years (kg) mean (SD)  76 (20) 75 (18) p=0.65
Health service use
Peeters, Van Zuilen 
(2011, 2012, 2014)
Nurse-led care Visits per year at 2 years (mean, SD) 7.0 (2.9) 4.7 (2.9) p<0.001
Nurse practitioner visits per year at 2 years (mean, SD) 4.2 (1.4) 1.0 (0.4) Not Reported
Physician visits per year at 2 years (mean, SD) 2.8 (2.2) 3.7 (2.9) p<0.001
Harris (1998) Multidisciplinary 
specialist care
Hospitalisations at 3-5 years (mean, SD) 1.3 (1.8) 1.3 (2.1) p=0.94
Emergency department visits at 3-5 years (mean, SD) 2.6 (3.5) 2.8 (5.0) p=0.52
Outpatient clinic visits at 3-5 years (mean, SD) 26.0 (28.0) 18.0 (19.0) p<0.001
Chen (2011) Self-management 
support
Hospitalisations  at 12 months (number, %) 5 (18.5) 12 (44.5) p<0.05
